|SC 13G/A||amended statement of beneficial ownership||Feb 14, 2014||41.9 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 14, 2014||82.3 KB|
|SC 13G/A||amended statement of beneficial ownership||Feb 7, 2014||26.3 KB|
|SC 13G/A||amended statement of beneficial ownership||Jan 31, 2014||26.3 KB|
|SC 13G/A||amended statement of beneficial ownership||Jan 16, 2014||51.1 KB|
|4||wyrick, susan d.||Dec 2, 2013||25.3 KB|
|10-Q||quarterly report||Nov 7, 2013||442.1 KB|
|8-K||current report||Nov 7, 2013||58.5 KB|
|4/A||jacobs cindy||Oct 7, 2013||25.0 KB|
|4/A||jacobs cindy||Oct 7, 2013||24.3 KB|
|4/A||cormack scott daniel||Oct 7, 2013||25.1 KB|
|4/A||cormack scott daniel||Oct 7, 2013||22.9 KB|
|4/A||wyrick susan d.||Oct 3, 2013||28.0 KB|
|4||wyrick, susan d.||Aug 15, 2013||27.2 KB|
|4||cormack, scott daniel||Aug 15, 2013||27.4 KB|
|4||jacobs, cindy||Aug 15, 2013||26.4 KB|
|S-8||registration statement||Aug 8, 2013||70.1 KB|
|10-Q||quarterly report||Aug 8, 2013||446.8 KB|
|8-K||current report||Aug 8, 2013||65.2 KB|
|4||goldstein, jack||Aug 8, 2013||24.7 KB|
- Corporate Governance
- Management & Board
- Stock Information
- SEC Filings
- Quarterly Results
- Analyst Coverage
- Webcasts & Presentations
- Scientific Publications & Presentations
- Frequently Asked Questions
© 2004-2014 OncoGenex Pharmaceuticals Inc. All rights reserved.
OncoGenex product candidates are investigational drugs for use only in approved clinical trials.
OncoGenex Pharmaceuticals is a drug discovery and development company uniquely focused on the challenge of cancer treatment resistance.
OncoGenex is uniquely focused on the challenge of cancer treatment resistance. We currently have several on-going clinical trials that may be of interest to you.
OncoGenex focuses on diverse molecular entities that target mechanisms of resistance and that have the potential to re-define treatment paradigms in a variety of cancers.
OncoGenex develops novel compounds designed to meet the persistent challenge of treatment resistance across a variety of cancers.